Our results indicate that there is no direct effect on OPC survival and proliferation but that the presence of endogenous TRPA1 agonists would impede remyelination in demyelinating lesions occurring in Multiple Sclerosis or other neurodegenerative diseases. This evidence concerns the gene TRPA1 and multiple sclerosis.